Clinical Trials Logo

Migraine clinical trials

View clinical trials related to Migraine.

Filter by:

NCT ID: NCT04019496 Completed - Migraine Clinical Trials

Neurophysiology of Prophylactic Treatment in Migraine

Start date: January 29, 2019
Phase:
Study type: Observational

This study aims to improve the pathophysiological understanding of migraine in in a longitudinal observational study investigating changes of established neurophysiological and imaging parameters in line with changes of the clinical phenotype. The study's focus is the investigation of mechanisms that are directly related to the cyclic character of migraine and its core structures. In this context, the primary endpoint is a change in the nociceptive blink reflex, an established brain stem reflex to study the trigemino-spinal system, associated with changes in migraine frequency and severity. In order to reliably detect changes in the trigeminal pain system, investigations are performed in patients before starting a prophylactic therapy and 3 months afterwards. Several secondary endpoints are used to evaluate changes of multimodal sensory and cortical information processing. Cerebral imaging will include examinations of structural and network effects of altered migraine disease activity.

NCT ID: NCT04017741 Completed - Migraine Clinical Trials

A Study Investigating the Efficacy of GON Blocks.

Start date: February 14, 2018
Phase: Phase 4
Study type: Interventional

Greater occipital nerve block ("GON block") is carried out extensively in the treatment of chronic migraine, but more research is required to understand the effectiveness of the procedure. It consists of a superficial injection of local anaesthetic and steroid around a nerve at the back of the head that supplies sensation to part of the scalp. This study intends to provide more detailed information on the effectiveness, safety and tolerability of GON block with local anaesthetic and steroid in patients with chronic migraine. It does this by comparing it to a dummy (placebo) procedure (a needle is inserted near the nerve, but no therapeutic substance is injected). It is a "cross-over study": all patients will receive both the GON block and the dummy procedure (not necessarily in that order), with a period in between to assess the response to the first injection. The GON block will entail an injection of 2 mls of 2% lidocaine (a local anaesthetic) and 80 mg of DepoMedrone (a steroid) through a fine needle (a total of 4 mls). The dummy procedure will consist of an injection of 4 mls of normal saline (a solution of common salt and water) through a fine needle. Patients will be followed up at various time points throughout 6 months whilst being enrolled on the study.

NCT ID: NCT04012593 Completed - Migraine Clinical Trials

Diary-based Study on the Course of Hormone-withdrawal Migraines

Start date: January 2017
Phase:
Study type: Observational

Single centered diary-based study to identify course and characteristics of hormone withdrawal headaches/migraines in users of combined hormonal contraceptives Objectives of the Research Project: to identify the course and characteristics of hormone withdrawal headaches/migraines in users of combined hormonal contraceptives (CHC)

NCT ID: NCT04012047 Completed - Migraine Clinical Trials

Headache Inducing Effect of Levcromakalim in Migraine With Aura Patients

Start date: July 9, 2019
Phase: N/A
Study type: Interventional

To investigate the role of KATP channels in migraine with aura patients.

NCT ID: NCT03999060 Completed - Migraine Clinical Trials

Trigeminal Brainstem Mapping

Start date: June 28, 2019
Phase: N/A
Study type: Interventional

To what extent the somatotopy of the 3 branches of the trigeminal nerve (V1,V2,V3) as well as the greater occipital nerve (GON) in the brainstem but also in the thalamus and the insula can be mapped using functional imaging and BOLD in humans is not known but might play an important role in imaging headache diseases. The aim is to map their somatotopy by random stimulation of V1, V2, V3 and the GON with painful electrical input during acquisition of BOLD-fMRI.

NCT ID: NCT03988088 Completed - Migraine Clinical Trials

A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine

Start date: July 22, 2019
Phase: Phase 1
Study type: Interventional

The purpose of the study is the measure the levels of lasmiditan in the body of children aged 6 to 17 with migraine. The study also will also examine the safety and tolerability of lasmiditan in children aged 6 to 17 with migraine. The study will last about 6 weeks, and includes 4 visits.

NCT ID: NCT03978403 Completed - Migraine Clinical Trials

A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers

Start date: May 29, 2019
Phase: Phase 1
Study type: Interventional

This is a single-center, open-label, randomized, four-way crossover study. Subjects will receive the four study treatments once, followed by in-clinic monitoring and extensive pharmacokinetic analysis. Dosing occurs ~48 hours apart from patch application, in randomized order. Subjects will have final assessment and be dismissed from the study.

NCT ID: NCT03962738 Completed - Migraine Clinical Trials

A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine

MONONOFU
Start date: May 31, 2019
Phase: Phase 2
Study type: Interventional

This study will assess the efficacy and safety of lasmiditan in the acute treatment of a migraine attack in Japanese adult participants with or without aura.

NCT ID: NCT03902496 Completed - Migraine Clinical Trials

Optical Treatment of Migraines Using the Avulux™ Optical Filter in the Form of Spectacle Lenses.

Start date: March 18, 2019
Phase: N/A
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of the Avulux device in reducing the impact of migraine headaches as measured by improvement in Headache Impact Test (HIT-6TM) scores at three weeks when compared to a control/sham device.

NCT ID: NCT03901482 Completed - Migraine Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

EMERGE
Start date: June 24, 2019
Phase: Phase 3
Study type: Interventional

Study STS101-002 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine